" class="no-js "lang="en-US"> Biogen - Medtech Alert
Wednesday, September 27, 2023
Biogen | Pharmtech Focus


About Biogen


Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases.

Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.

With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

Related Story

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Great Britain

May 22 2023

Eisai and Biogen announced today that Eisai has submitted a Marketing Authorization Application (MAA) for […]

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

February 28 2023

Eisai and Biogen announced today that the Biologics License Application (BLA) for lecanemab, an investigational […]

Alzheimer's Association Statement on Lecanemab Phase 3 Full Results

November 30 2022

The Alzheimer’s Association welcomes, and is further encouraged by the full Phase 3 data presented […]

Samsung Biologics Reaches Agreement with Biogen to Acquire Full Ownership of Samsung Bioepis

January 28 2022

Samsung Biologics (KRX: 207940.KS) announced today that it has reached an agreement with Biogen for the buyout […]

FDA Approval of Aducanumab

June 10 2021

Neurimmune welcomes the news that the U.S. Food and Drug Administration (FDA) has approved Biogen‘s […]

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

April 12 2021

Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a […]